Navigation Links
First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers

Two compounds that zero in on cancer cells spreading throughout the body, while ignoring primary tumor cells, could someday give doctors a whole new weapon in the fight against tough-to-treat metastatic disease, according to Weill Medical College of Cornell University researchers.

The compounds, called synthetic migrastatin analogues, prevented 91 to 99 percent of metastatic breast cancer cells in mice, and are the first to target only metastatic cells.

"They're unbelievably effective, and in vitro study suggests they'll work just as well at inhibiting the migration of prostate and colon cancer cells," said senior researcher Dr. Xin-Yun Huang, Professor of Physiology and Biophysics at Weill Cornell Medical College in New York City.

The findings have just been published in Proceedings of the National Academy of Sciences.

For decades, doctors have fought cancer by using surgery, chemotherapy, or radiation to excise or shrink the primary tumor.

"However, in too many cases it's simply impossible to completely remove the tumor," Dr. Huang explained. "So recently the idea of targeting cell migration -- metastasis -- has become an alternative strategy that's gained a lot of interest among researchers."

If compounds could be found that slowed or halted cancer spread, doctors could gain valuable time in shrinking the primary tumor. "If we had the luxury of time, we could treat that primary tumor at lower doses, too, with fewer side effects for the patient," Dr. Huang said.

Until now, agents that specifically target metastatic cells have remained elusive. However, a new avenue of research opened up when Dr. Huang's team noticed that the Streptomyces bacterium -- the bug that gives us the antibiotic streptomycin -- also produces a natural compound called migrastatin, which appears to inhibit cell migration.

Natural migrastatin's effect is relatively weak, but Dr. Huang suspected the molecule might be manipulated in to something more potent. In collaboration with the laboratory of Dr. Samuel Danishefsky at the Memorial Sloan-Kettering Cancer Center, the team went to work creating what's called a "synthetic analogue."

"Starting with the basic migrastatin molecule, we cut a piece there, add a piece here," he explained, "and what we ended up with were two compounds -- core macroketone and core macrolactam -- that are about 1,000 times more powerful at inhibiting cancer cell migration."

In fact, in a mouse model, the analogues were between 91 to 99 percent effective in stopping the spread of breast cancer cells, the researchers report. Cell culture studies suggest they can reproduce that success in a wide range of other cancers, too.

"What's unique about these analogues is that they do all this without affecting primary tumor cells, or their blood supply," Dr. Huang said. "To our knowledge, that's a real first."

Exact mechanisms remain unclear.

"Obviously, these compounds are targeting some step in the cell-migration process," Dr. Huang said. The activity of a migration-linked protein called Rac appears to be much reduced in cancer cells affected by the analogues, and the researchers also noticed that malignant cells failed to grow tiny "antennas," called lamellipodia, another crucial step in the migration process.

"Therefore, the migrastatin analogues must be working on something upstream of those two important steps," Dr. Huang said.

Dr. HuangÕs next important step is moving these analogues into clinical trials.

"We're trying right now to get a company interested in this, especially because the mice used in our trial seemed to experience minimal toxicity -- a good sign that patients might tolerate these compounds, too," Dr. Huang said.

"It's all very exciting," he said. "Metastatic disease is such a tough problem, and these compounds could provide patients with a brand new kind of hope."

The research was funded by grants from the National Institutes of Health.

Co-researchers included Ms. Dandan Shan (first author), Mr. Lin Chen, and Dr. Xiaojing Ma, of Weill Cornell Medical College; and Dr. Jon T. Njardarson, Dr. Christoph Gaul, and Dr. Samuel Danishefsky, of Memorial Sloan-Kettering Cancer Center, New York.


Source:Cornell University

Related biology news :

1. First-ever genomic test predicts which lung cancer patients need chemotherapy to live
2. Compounds in plastic packaging act as environmental estrogens altering breast genes
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. Potential Drug Target For Treating Cocaine Abuse Found
5. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
6. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
7. New Therapeutic Target Identified In Inherited Brain Tumor Disorder
8. Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates
9. Targeted virus compels cancer cells to eat themselves
10. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
11. Targeting tumors the natural way
Post Your Comments:

(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, Inc., ... U.S. distribution of its DNA library preparation products, ... Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has ... preparation of NGS libraries for liquid biopsies--the analysis ... and prognostic applications in cancer and other conditions. ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... ... 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for production, ... to serve as Chief Operating Officer. , Having joined InSphero in November ... and was promoted to Head of InSphero Diagnostics in 2014. There she has ...
(Date:11/24/2015)... 24, 2015  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... company,s president and chief executive officer, will present at the ... in New York City . The presentation ... 1, 2015 at 9:30 a.m. EST. ... website at least 15 minutes prior to the presentation to ...
Breaking Biology Technology: